CD4 and experimental autoimmune encephalomyelitis: Fingolimod efficiently reduces MS relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors [2,3], which is consistent with findings in an animal model of MS that fingolimod successfully reduced the infiltration of myelin antigen-specific CD4+T cells into inflammatory sites in experimental autoimmune encephalomyelitis [4].